SAN JOSE, Calif., July 6, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, announced today that the United States District Court for the Northern District of California denied the preliminary injunction motion filed against Ariosa Diagnostics by Sequenom, Inc. In its preliminary injunction motion, Sequenom sought to enjoin Ariosa Diagnostics from offering or selling its Harmony™ Prenatal Test, pending the ultimate resolution of the litigation between Ariosa Diagnostics and Sequenom. "Ariosa Diagnostics has vigorously opposed Sequenom's drastic attempt to bar Ariosa from competing with our Harmony Prenatal Test, and we feel pleased and vindicated by the Court's order denying Sequenom's preliminary injunction motion," said Dr. Ken Song, Ariosa Diagnostics' Chief Executive Officer. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) About Ariosa Diagnostics (formerly Aria Diagnostics) Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety. The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. SOURCE Ariosa Diagnostics, Inc.